US biotech company Sage Therapeutics is to slash a third of its remaining jobs - just a year after cutting 40% of its prior workforce.

Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...

After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its ...

The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.

Sage Therapeutics said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 ...

Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...

Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...

Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus ...

Sage and Biogen last year won Food and Drug Administration approval of Zurzuvae as the first pill to treat postpartum depression, but the agency rejected the drug for major depressive disorder, a much ...

The biopharmaceutical company says the reorganization is meant to strengthen its balance sheet and position it for long-term ...

Sage Therapeutics announces a reorganization to support product launch and pipeline development, resulting in a workforce ...

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...